Previous cost-effectiveness studies of cholinesterase inhibitors have modeled Alzheimer's disease (AD) progression and treatment effects through single or global severity measures, or progression to "Full Time Care". The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.